In the second reporting period, AAVolution also strengthened its activities beyond the core scientific objectives through effective coordination, communication, and portfolio engagement. The consortium maintained transparent and efficient project governance, achieved key communication milestones including updated promotional materials and the successful organisation of the Second Annual Meeting, and submitted a revised Data Management Plan reinforcing its commitment to open science, FAIR data principles, and Horizon Europe compliance. At the same time, the project management team continued monitoring the implementation of the IP and Exploitation Plan, while the Technology Transfer Office actively worked with partners to identify and support protectable results. At portfolio level, AAVolution further consolidated its strategic role within the EIC Cell and Gene Therapy Portfolio by contributing to joint planning, participating in strategic meetings, and confirming its role as organiser of the 2026 Annual Portfolio Meeting in Pozzuoli, Italy. The project also engaged with key regulatory and industrial stakeholders through EMA- and FDA-related webinars, interactions with manufacturing and commercialization experts, and exchanges with initiatives such as the Novo Nordisk Foundation’s Cellerator programme. These activities strengthened AAVolution’s regulatory preparedness, visibility, translational positioning, and integration within the broader European cell and gene therapy innovation ecosystem.
